In response to an application filed with the U.S. Patent and Trademark Office, neurodiagnostics developer CereScan has broadened the parameters on its automated diagnostic assistance and intelligent support system, CereMetrix, which uses quantitative measurements to assist in the diagnosis and study of complex brain disorders.

Through award of a second patent, the company may now claim exclusive use of its neuroimaging database systems and methods in the measurement of all types of brain activity. The patent expands CereScan's intellectual property and use of its wholly owned data warehouse along with associated biomarkers, patient demographic and clinical information worldwide.

"CereScan is transforming the future of advanced brain diagnostics and use of intelligent learning to benefit those suffering from and studying complex brain disorders," said John Kelley, CEO and chairman of CereScan. "The expansion of our patent allows us to apply key learnings to all manners of brain measurement and vastly expands the potential for advancements in brain science using technology."

CereScan combines patient-clinical information, functional brain imaging and advanced processing software to help medical professionals identify abnormal brain physiology and activity using correlative data and pattern matching contained within its extensive data warehouse.

CereScan is a developer of brain imaging technology.